179 related articles for article (PubMed ID: 29924031)
21. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer.
Sastre J; Argilés G; Benavides M; Feliú J; García-Alfonso P; García-Carbonero R; Grávalos C; Guillén-Ponce C; Martínez-Villacampa M; Pericay C
Clin Transl Oncol; 2014 Nov; 16(11):942-53. PubMed ID: 25223744
[TBL] [Abstract][Full Text] [Related]
22. The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.
Roberto M; Falcone R; Mazzuca F; Archibugi L; Castaldi N; Botticelli A; Osti MF; Marchetti P
Medicine (Baltimore); 2017 Dec; 96(48):e9023. PubMed ID: 29310420
[TBL] [Abstract][Full Text] [Related]
23. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
[TBL] [Abstract][Full Text] [Related]
24. Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
Komori A; Taniguchi H; Hamauchi S; Masuishi T; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
Oncology; 2017; 93(5):329-335. PubMed ID: 28866662
[TBL] [Abstract][Full Text] [Related]
25. Regorafenib in metastatic colorectal cancer.
Sartore-Bianchi A; Zeppellini A; Amatu A; Ricotta R; Bencardino K; Siena S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):255-65. PubMed ID: 24559322
[TBL] [Abstract][Full Text] [Related]
26. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
Kopeckova K; Buchler T; Bortlicek Z; Hejduk K; Chloupkova R; Melichar B; Pokorna P; Tomasek J; Linke Z; Petruzelka L; Kiss I; Prausova J
Target Oncol; 2017 Feb; 12(1):89-95. PubMed ID: 27638381
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
[TBL] [Abstract][Full Text] [Related]
28. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
29. Molecular insight of regorafenib treatment for colorectal cancer.
Arai H; Battaglin F; Wang J; Lo JH; Soni S; Zhang W; Lenz HJ
Cancer Treat Rev; 2019 Dec; 81():101912. PubMed ID: 31715423
[TBL] [Abstract][Full Text] [Related]
30. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Köstek O; Hacıoğlu MB; Sakin A; Demir T; Sarı M; Ozkul O; Araz M; Doğan AF; Demircan NC; Uzunoğlu S; Çiçin İ; Erdoğan B
Cancer Chemother Pharmacol; 2019 Jan; 83(1):115-122. PubMed ID: 30374523
[TBL] [Abstract][Full Text] [Related]
31. The prognostic role of polypharmacy in metastatic colorectal cancer patients treated with regorafenib.
Yekedüz E; Aktaş EG; Köksoy EB; Doğan N; Ürün Y; Utkan G
Future Oncol; 2022 Mar; 18(9):1067-1076. PubMed ID: 35109668
[TBL] [Abstract][Full Text] [Related]
32. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
34. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
[TBL] [Abstract][Full Text] [Related]
35. Predictive Value of Early Tumor Shrinkage and Density Reduction of Lung Metastases in Patients With Metastatic Colorectal Cancer Treated With Regorafenib.
Vanwynsberghe H; Verbeke X; Coolen J; Van Cutsem E
Clin Colorectal Cancer; 2017 Dec; 16(4):377-380. PubMed ID: 28454726
[TBL] [Abstract][Full Text] [Related]
36. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?
García-Alfonso P; Feliú J; García-Carbonero R; Grávalos C; Guillén-Ponce C; Sastre J; García-Foncillas J
Clin Transl Oncol; 2016 Nov; 18(11):1072-1081. PubMed ID: 27037815
[TBL] [Abstract][Full Text] [Related]
37. The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong.
Lam KO; Lee KC; Chiu J; Lee VH; Leung R; Choy TS; Yau T
Postgrad Med J; 2017 Jul; 93(1101):395-400. PubMed ID: 27836933
[TBL] [Abstract][Full Text] [Related]
38. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting.
Unseld M; Filip M; Seirl S; Gleiss A; Bianconi D; Kieler M; Demyanets S; Scheithauer W; Zielinski C; Prager G
Neoplasma; 2018; 65(4):599-603. PubMed ID: 29940763
[TBL] [Abstract][Full Text] [Related]
39. Clinical and molecular assessment of regorafenib monotherapy.
Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
[TBL] [Abstract][Full Text] [Related]
40. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
